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ABSTRACT 25 
Buccal films were prepared from aqueous and ethanolic Metolose gels using the solvent casting 
approach (40°C). The hydration (PBS and simulated saliva), mucoadhesion, physical stability 
(20°C, 40°C), in vitro drug (omeprazole) dissolution (PBS and simulated saliva), ex vivo 
permeation (pig buccal mucosa) in presence of simulated saliva, ex vivo bioadhesion and cell 
viability using MTT of drug loaded (DL) films were investigated. Hydration and mucoadhesion 30 
results showed that swelling capacity and adhesion was higher in the presence of PBS than 
simulated saliva (SS) due to differences in ionic strength. Omeprazole was more stable at 20°C 
than 40°C whilst omeprazole release reached a plateau within 1 hour and faster in PBS than in 
SS. Fitting release data to kinetic models showed that Korsmeyer-Peppas equation best fit the 
dissolution data. Drug release in PBS was best described by zero order via non-Fickian 35 
diffusion but followed super case II transport in SS attributed to drug diffusion and polymer 
erosion. The amount of omeprazole permeating over 2 hours was 275ug/cm2 whilst the 
formulations and starting materials showed cell viability values greater than 95%, confirming 
their safety for potential use in paediatric buccal delivery. 
 40 
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1. INTRODUCTION 
The development of age appropriate formulations for paediatric populations is of current 
topical interest and buccal films have been proposed as suitable alternatives to traditional 
dosage forms such as tablets and liquids (Lui et al., 2014, Khan et al., 2015). An ideal and 
effective buccal dosage form is required to possess certain functional properties including 55 
bioadhesion (mucoadhesion), hydration and swelling upon imbibing saliva, drug release from 
the swollen gel and eventual permeation through the buccal membrane (Boateng et al., 2014).  
Formulations prepared using mucoadhesive polymers have gained significant interest 
because of the well-established advantages including prolonging the residence time of the 
dosage form at the site of application (Tiloo et al., 2011). The process of mucoadhesion 60 
involves wetting and swelling of polymer, interpenetration between the polymer chains and the 
mucosal membrane and formation of chemical bonds between the entangled chains and mucin 
(Palacio et al., 2012). There are several approaches used to assess the mucoadhesive 
performance of polymeric dosage forms including texture analyser (Thirawong et al., 2007; 
Ayensu et al., 2012),  rheometry (Tamburic and Craig, 1997) and chemometrics (Boateng et 65 
al., 2015).  The texture analyser technique (TA) assesses the stickiness, the total work of 
adhesion (TWA) and the cohesiveness of the dosage forms. Stickiness is described as the 
maximum force (peak adhesive force –PAF)) required to separate the probe attached to the 
formulation from the mucosal substrate whereas, the total amount of work exerted in detaching 
the probe from the mucosal substrate is referred to as work of adhesion and is calculated from 70 
the area under the force versus distance curve. Cohesiveness is defined as the intermolecular 
attraction between the mucosal substrate and formulation, and determined by the travel distance 
in mm on the force versus distance plot (Thirawong et al., 2007). 
Hydration (swelling) is the process that occurs when hydrophilic polymers spread over 
the surface of a mucosal membrane in order to produce direct contact with the membrane. 75 
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Hydration and eventual swelling occurs because the individual component chains situated 
within the polymer network have an affinity for water and this forms an important stage in 
mucoadhesion as well as affecting other functional characteristics such as drug release. 
(Boateng & Ayensu, 2014).  
Drug release is affected by several factors such as physico-chemical properties of the 80 
drug, dissolution environment, structural characteristics of the polymeric system and the 
possible interactions between these factors as described by Fu and Kao, (2010). In the case of 
swelling controlled drug release systems such as polymer films, a drug is molecularly dispersed 
within the formulation matrix. Penetration of water (or dissolution medium such as saliva) into 
the polymer matrix causes the formulation to swell to form a gel and drug diffusion through 85 
the swollen polymer matrix is the main driving force controlling the release of drug from the 
system (Langer & Robison, 1986). However, to understand the mechanism of drug release, 
various mathematical models are used to study and evaluate the overall kinetics of drug release 
from polymeric dosage forms such as films (Dash et al., 2010).  
The main barrier to a drug intended for systemic activity following release from a given 90 
buccal formulation, is the buccal mucosa and epithelial membrane, which the drug must cross 
to reach the systemic circulation. Various in vivo and ex vivo models for investigating drug 
permeation through the buccal mucosa have been reported for different animals such as hamster 
(Eggerth et al., 1987), rabbit (Nair & Chien, 1993; Dowty et al., 1992), dog (Galey et al., 1976), 
pig (Chen et al., 1999; Artusia et al., 2003; Sandri et al., 2004) and sheep (Giovino et al., 2013, 95 
Boateng & Ayensu., 2014). However, the buccal epithelium of rodents such as hamsters is 
thick and keratinised and the surface area is small (Shojaei 1998), which limits the extent of 
drug permeation. Though the dog’s buccal mucosa is non keratinised and similar to human 
buccal epithelium, it is expensive for routine use in in vivo permeation experiments (Shojaei, 
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1998), whilst their use as the most common household pet, makes their availability for ex vivo 100 
experiments, very expensive.  
However, pig buccal mucosa is also non-keratinised and closest to human tissue in 
terms of structure and permeability (Franz-Motan et al., 2015). It is smooth and intact and 
consists of stratified, squamous, epithelium supported on a connective-tissue layer (Squier & 
Kremer, 2001). In addition, its low cost for in vivo studies and ready availability in local 105 
butcheries for ex vivo experiments, makes the porcine buccal mucosa an ideal model for drug 
permeation studies. The porcine oesophageal mucosa is smooth and intact and consists of 
stratified, squamous, non-keratinised epithelium supported on a connective-tissue layer (Squier 
& Kremer., 2001). Various studies have reported on permeation through pig buccal mucosa for 
different drugs including fentanyl citrate (del Consuelo et al., 2005), beta blockers (Amores et 110 
al., 2014), propofol (Tsagogiorgas et al., 2013) and galantamine (De Caro et al., 2008).  
  In addition to the above functional characteristics, buccal formulations for paediatric 
patients are required to be non- toxic, for example, they should not irritate or cause permanent 
damage to the buccal mucosa membrane, with continuous application (Liu et al., 2014). Cell 
viability assays are used for drug screening and cytotoxicity tests for chemicals, and 115 
pharmaceutical formulations. Specific cell cultures can be used to screen for toxicity by 
estimation of the basal function of the cell and such testing using specialised cells have proven 
most useful when the in vivo toxicity of a chemical is already well established (Ekwall et al., 
1990). 
Omeprazole (OME) is an effective short-term treatment for gastric and duodenal ulcers and 120 
used in combination with antibiotics for eradication of Helicobacter pylori (Stroyer et al., 
2006). An initial short course of OME is the treatment of choice in gastro-oesophageal reflux 
disease with severe symptoms; children with endoscopically confirmed erosive, ulcerative, or 
stricturing (narrowing or tightening) of oesophagus (Fass et al., 1998). OME is effective in 
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the treatment of Zollinger-Ellison syndrome and is used to reduce the degradation of 125 
pancreatic enzyme supplements in children with cystic fibrosis (Nishioka et al., 1999). In 
aqueous solution its stability is entirely dependent on the initial pH and in acidic and neutral 
conditions, it is rapidly degraded. To prevent degradation of the drug in the acid medium of 
the stomach, the drug is formulated as enteric-coated granules in capsule form (Lind et al., 
1983). Although OME is well absorbed from the gastrointestinal tract, its oral bioavailability 130 
in humans is about 40 to 50% suggesting pronounced first pass metabolism for this drug. This 
makes OME a good candidate for buccal drug delivery where it can avoid both first pass 
metabolism and gastric acid degradation and was therefore chosen as the model drug in this 
study. 
Metolose (MET) is a non-ionic cellulose ether comprising methylcellulose and three 135 
substitution types of HPMC each available in several grades with varying viscosities. Key 
properties of MET include solubility in cold water, formation of transparent solutions and 
forming reversible gels during heating due to its viscoelastic properties, with the formed gel 
maintaining its shape during the heating. MET can produce transparent films by casting from 
their gel solutions (Roy et al., 2009).  140 
 
In this study, the functional characteristics (swelling, mucoadhesion and stability) of 
optimised films prepared using metolose (MET), intended for paediatric drug delivery, have 
been investigated. Further, in vitro drug dissolution properties (and release mechanisms), the 
ex vivo permeation of omeprazole (OME) released from the MET films across pig buccal tissue, 145 
in vitro bio-adhesion of the films on the buccal membrane and cell toxicity using MTT assay 
have been characterised. 
 
2. MATERIALS AND METHODS 
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2.1 Materials 150 
Metolose (MET) was obtained from Shin Etsu (Stevenage, Hertfordshire, UK), polyethylene 
glycol (PEG 400), L-arginine (L-arg), gelatine and mucin from bovine submaxillary gland, 
Type I-S, Krebs-Ringer bicarbonate buffer, thiazolyl blue tetrazolium bromide, MTT reagent 
[(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] and dimethyl sulfoxide 
(DMSO) were obtained from Sigma-Aldrich (Gillingham, UK). Omeprazole (OME) was 155 
obtained from TCI (Tokyo, Japan). Ethanol, potassium di-hydrogen phosphate, sodium 
hydroxide, sodium chloride, sodium phosphate di-basic were all obtained from Fisher 
Scientific (UK). Dulbecco’s Modified Eagles Medium (DMEM), foetal bovine serum (FBS), 
penicillin, streptomycin and glutamine were all obtained from Gibco (Paisley, UK).  
 160 
2.2 Formulation development  
The films were prepared from metolose (MET) gels containing omeprazole (OME) (0.2% 
w/w), L-arginine (L-arg) (0.4% w/w) with or without PEG 400 (0 and 0.5% w/w). The 
formulations prepared are summarised in table 1. Blank films were prepared by dissolving the 
required amount of PEG in 20% v/v ethanol to yield 0.00 or 0.5% w/w PEG solution and heated 165 
to 40°C). The required amount of MET (0.5g) was added to 50mL PEG solution to yield 1% 
w/w MET gel. For the DL films, OME (0.1g) and L-arg (0.2g) as stabiliser were added to 50mL 
of 20% v/v ethanol to yield homogeneous OME-L-arg solution. The required weight (0.5g) of 
polymer to achieve 1% w/v gel was added to the OME, L-arg solution (22°C) and continuously 
stirred till complete hydration and then heated to 40°C. Based on the total weight of polymers, 170 
different amounts of PEG were added to obtain different concentrations (0.00%, 0.50%) in the 
final gels prepared. Stirring was continued for 30 min to achieve a homogeneous dispersion 
and the gels were left to stand overnight to remove entrapped air bubbles. 20 g was poured into 
Petri dishes (86 mm diameter) and dried at 40°C to obtain the final films.  The films obtained 
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were visually examined and it was observed that the unplasticised films were brittle and 175 
difficult to cut into strips for further testing and therefore all subsequent tests were performed 
using only the plasticised films (with the exception of MTT assay). 
 
2.3 Hydration (swelling) capacities 
The hydration (swelling) capacities of the plasticised blank (BLK) and drug loaded (DL) films 180 
with the model drug (OME) and stabiliser (L-arg) were determined in two different media 
[(0.01M PBS solution (pH 6.8 ± 0.1) and simulated saliva (SS) (pH 6.8 ± 0.1)] and both set at 
a temperature of 37 ± 0.1°C. The buffer solution was prepared by dissolving 6.80g of potassium 
dihydrogen phosphate in 1L of deionised water and adjusting the pH to 6.8 using sodium 
hydroxide. SS solution was prepared by dissolving potassium dihydrogen phosphate (0.19g), 185 
sodium chloride (8.00g) and sodium phosphate dibasic (2.38g) in 1L of deionised water and 
adjusting the pH to 6.8 using phosphoric acid. The films were cut into 2 × 2 cm2 strips and 
placed into small Petri-dishes containing 10mL of the media (PBS or SS) and initially weighed. 
It should be noted that the DL films used were similar to samples used for drug dissolution 
studies (below) with drug loading determined to ensure homogeneity. At predetermined time 190 
intervals (5 minutes) the liquid media was removed using a syringe, excess media blotted off 
with tissue paper and weighed again. After the weight of hydrated film had been recorded, 
10mL of fresh medium (PBS or SS) was placed back in the Petri dish using a syringe and the 
process continued. These studies were performed in triplicate (n = 3) for each set of formulated 
samples and average values were calculated for data analyses. The % swelling capacity 195 
(swelling index) was calculated using the equation below: 
𝑆𝑤𝑒𝑙𝑙𝑖𝑛𝑔 𝐼𝑛𝑑𝑒𝑥(%) =
𝑊𝑠−𝑊
𝑊
× 100     Equation 1 
Where Ws is the weight of the film before hydration and Ws the initial weight of the film after 
hydration. 
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2.4 In vitro mucoadhesion using gelatin gel substrate with texture analyser  
The in vitro mucoadhesion experiments were performed on BLK and DL films with a TA HD 
plus Texture Analyser (Stable Micro Systems, Surrey, UK) fitted with a 5kg load cell. The film 
was attached to an adhesive rig probe (75mm diameter) with the help of double sided adhesive 
tape. An 88mm diameter Petri dish was filled with 20g of gelatine solution (6.67% w/w) and 205 
allowed to set as a solid gel and the surface of the gel was equilibrated with 0.5 ml of SS (pH 
6.8) or PBS (pH 6.8) and both used to represent the buccal mucosa (Boateng et al., 2014). The 
film was positioned in contact with the equilibrated gelatine gel for 60 seconds to provide 
optimal contact and then detached to determine adhesive properties using the following 
settings: pre-test speed 0.5mm/s; test speed 0.5 mm/s; post-test speed 1.0mm/s; applied force 210 
1N; contact time 60.0s; trigger type auto; trigger force 0.05N and return distance of 10.0mm. 
Texture Exponent 32 software was used to record and process the data. The stickiness or peak 
adhesive force (PAF) required to separate the film from the mucosal surface, total work of 
adhesion (TWA) and cohesiveness of the samples were determined from the force distance 
plots. 215 
 
2.5 Drug stability 
OME stability of DL MET films were determined using two different storage conditions 
according to ICH (2003) guidelines. Samples were placed in humidity controlled desiccators 
(using activated silica gel) and placed in an oven (40°C) and at room temperature (ambient) 220 
and the stability studied over 3 months. The films were wrapped with aluminium foil due to 
the light sensitivity of OME. An Agilent1200 HPLC equipped with auto sampler (Agilent 
Technology, Cheshire, UK) with Chemstation® software program was used to determine the 
amount of drug present in the films after storing under the two sets of conditions. 
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For HPLC analysis, the samples stored under the various stability conditions above, 225 
were weighed (5mg) and dissolved using 0.01M PBS solution (pH 6.8 ± 0.1) in volumetric 
flasks (10mL). The 5mg strips were cut from a given section of each film prior to stability 
testing for each time point 1mL aliquots from each flask was sampled and placed into HPLC 
vials for analysis. The stationary phase used for analysis was a Hypersil™ ODS C18 reversed 
phased column, 5µm particle size (250 x 4.6 mm) (Thermo Scientific, Hampshire UK). The 230 
mobile phase consisted of a mixture of ammonium acetate and acetonitrile in the ratio of 60:40 
v/v and a flow rate of 2mL/min and diode array UV detector wavelength for OME was set at 
302nm. 20μL volumes were injected during each run, respectively. The concentration of OME 
in each film sample was calculated from the linearized calibration curve (R2 > 0.99). 
 235 
2.6 In vitro drug dissolution studies 
2.6.1 In vitro release of OME using Franz-type diffusion cell 
The release profiles of drug from films prepared from gels containing 20% v/v ethanol, 0.5% 
w/w PEG 400,  OME and L-arg (OME:L-arg ratio was 1:2) were determined. The ratio of 1:2 
for OME:L-arg was chosen because it was previously determined to be the optimum 240 
concentration of the amino acid to prevent OME degradation whilst maintaining appropriate 
tensile properties (Khan et al., 2015). Before the dissolution studies, the content (assay) and 
uniformity of OME within the film was determined. This was measured by weighing the film 
accurately to 5mg (n = 3) and hydrated in 8mL each of two dissolution media (0.01M PBS pH 
6.8 and SS pH 6.8 at 37°C). The hydrated film was gently stirred at 37 ± 0.5°C until completely 245 
dissolved. The concentration of OME was analysed using HPLC as described in section 2.5 
above. 
In vitro drug dissolution studies were carried out using Franz-type diffusion cells. 5mg 
of optimised (plasticised) DL MET film were placed in the donor compartment on stainless 
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steel wire mesh (0.5 mm x 0.5 mm) which separated the donor and receiver compartments. The 250 
wire mesh acted both as a support for the film whilst allowing contact with the dissolution 
medium (Boateng et al., 2009). The mucoadhesive surface was in contact with the wire mesh 
and facing the receiver compartment of the Franz diffusion cell (Cui et al., 2008). Each receiver 
compartment was filled separately with 8mL of 0.01M PBS pH 6.8 or SS pH 6.8 with magnetic 
stirring at a speed of 250 rev/min. The two compartments were held together by a cell clamp 255 
and sealed with parafilm, in order to limit evaporation and the temperature of the diffusion cell 
was maintained at 37 ± 0.5°C and stirred throughout the experiment. 1mL of the dissolution 
medium was sampled at predetermined time intervals and replaced with the same amount of 
fresh medium to maintain a constant volume for 2 hours. The sampled dissolution medium was 
measured at 302nm using HPLC. The concentration of OME released from the film was 260 
determined by interpolation from the linearized calibration curve (R2 > 0.99) and cumulative 
percentage drug release profiles plotted against time in minutes.  
 
2.6.2 Drug release mechanisms 
Based on the drug dissolution data, four kinetic models with their corresponding relationships 265 
were constructed as shown in Table 2. The mathematical equations corresponding to the kinetic 
models are shown in equations 2 to 5 below. 
Zero order  
Qt = Q0 + k0 t         Equation 2 
Where  270 
Q0 = the initial amount of drugs 
Qt = cumulative amount of drug release time t 
K0 = zero order rate constant 
t = time in minutes 
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First order  275 
Log Qt = Log Q0 + kt/2.303       Equation 3 
Where  
Q0 = initial amount of drugs  
Qt = cumulative amount of drug release in time t  
K1 = first order rate constant  280 
t = time in minutes 
Higuchi  
Q =KH t 
½         Equation 4 
Q = cumulative amount of drug release in time (t) 
KH = Higuchi release rate constant  285 
t = time in minutes  
Korsmeyer-Peppas  
F = (M t //M) = K p t
n        Equation 5 
F = fraction of drug release in time (t) 
Mt = Amount of drug released at time (t) 290 
M = total amount of drug in dosage from  
Kp = release rate constant  
n = diffusion or release exponent  
t = time in minutes 
‘n’ is estimated from linear regression of log (Mt/M) versus log t. 295 
 
2.6.3 Comparison of release profiles 
Release parameters from the dissolution profiles for variables under investigation (PBS and SS 
media) were used to characterise the drug release data and compare the results in PBS and SS. 
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The parameters used were tx%, and sampling time. The tx% corresponds to the time necessary 300 
for the release of a determined percentage of drug (e.g., t20%, t50%, t80%). Sampling time 
corresponds to the amount of drug dissolved in that time (e.g., t20min,). In this study, the time to 
release 20% of the drug originally loaded (t20%) and the percentage cumulative release at 60 
minutes (t60min) were used to compare dissolution profiles in PBS and SS (Costa et al., 2001).   
 305 
2.7 Tissue preparation 
Buccal tissues (cheek) from pigs were obtained from a local slaughterhouse (Tunbridge Wells, 
Kent, UK). After removal, the tissues were immediately transferred into cold Krebs buffer (pH 
6.8) modified with sodium carbonate, placed in sealed ice box filled with dry ice and 
immediately transported to the laboratory. The buccal mucosa, with part of sub mucosa, was 310 
carefully separated from the fat and muscles using a sharp scalpel and the epithelium isolated 
from the underlying tissue. The thickness of the sample was approximately 500µm and the 
buccal mucosa was used within 2 hours (Patel et al., 2012).  
 
2.8 Ex vivo buccal permeation studies  315 
The mucosal membrane prepared above was washed with SS  at 37°C. The obtained buccal 
mucosa membrane was mounted between the donor and receiver compartments of the Franz-
type diffusion cell, with the epithelial side facing the donor compartment to allow contact with 
the film (Attia et al., 2004). The receiver chamber was filled with 8mL of SS  at 37°C and 
uniform mixing was provided by magnetic stirring at 250 rev/min. After an equilibration period 320 
of 30 minutes, 0.5mL SS was placed in the donor compartment and 5mg of the OME loaded 
film was placed in the donor chamber with the mucoadhesion layer in contact with the epithelial 
surface. The compartments were held together by a cell clamp accessory and sealed with 
parafilm to limit evaporation. At predetermined time intervals, aliquots (1mL) were withdrawn 
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from the sampling port of the receiver compartment and replaced with the same amount of SS 325 
to maintain a constant volume for 2 hours. The sampled aliquots were analysed using HPLC 
as described above (n=3) and the % cumulative permeation plotted against time. 
 
2.9 Ex-vivo mucoadhesion using porcine buccal tissue with texture analyser 
The ex vivo mucoadhesion experiments were performed on DL MET films (n = 3) to estimate 330 
the effect of PBS and SS on adhesion of the films on porcine buccal tissue. The samples were 
tested using a TA HD plus Texture Analyser (Stable Micro Systems, Surrey, UK) fitted with a 
5kg load cell following the procedure described in section 2.4 above. The peak adhesive force 
(PAF), TWA and cohesiveness of the sample were determined from the force-distance plots. 
 335 
2.10 MTT assay 
MTT assay on Vero cells was used to evaluate the cytotoxicity of pure MET, pure L-arg, pure 
OME, optimised BLK and DL films. Vero cells (ATCC®CCL-81TM) are adherent cells derived 
from the kidney of the African Green monkey (Cercopithecus aethiops) and are one of the 
commonly used mammalian cell lines in cell, microbiology and molecular biology 340 
(Ammerman et al., 2008). These cells were obtained from cell and tissue culture labs within 
the Faculty of Engineering and Science, (Richardson Lab, University of Greenwich, Medway) 
and stored at -80°C. The cells (Vero, 1x104cells/well) were used to seed a sterile, flat-bottomed 
96 well tissue culture plate with Dulbecco’s modified eagles medium (DMEM), Foetal bovine 
serum (FBS) 10% (v/v), penicillin (100units/mL), streptomycin (100μg/mL) and glutamine 345 
0.292mg/mL. Two cultures (treated and control) were kept under sterile conditions in a laminar 
hood) and incubated at 37°C in 5 % (v/v) CO2 for 24 hours.  
After 24 hours, the cells (except those in the control wells) were exposed to either pure 
MET, pure L-arg, pure OME, blank (BLK) or DL films  in cell culture medium)] and incubated 
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for 68 hours. This was used to replace the existing media covering the cells after the designated 350 
incubation period. MTT stock solution (5mg/mL) was prepared by dissolving 250mg of MTT 
reagent in 50mL of PBS (1x) buffer, and sterilized by passing it through a 0.22μm filter 
(Corning®, Germany). 10μL (equivalent to 50μg) of the MTT stock solution was added to each 
well and the plate incubated for a further 4 hours using the same incubator conditions as above 
bringing the total incubation time to 72 hours. The contents of the plate were decanted and 355 
100μL of DMSO was added to each well, incubated at room temperature for 30 minutes and 
the absorbance read on a Multi-scan EX Micro-plate photometer (Thermo Scientific, Essex, 
UK) at optical density (OD) of 540nm. Data obtained was expressed as percentage cell viability 
(mean ± standard error of the mean) for all the samples tested.  
 360 
2.11 Statistical analysis 
Statistical data analysis was performed to compare hydration and mucoadhesion results using 
two tailed student t-test with 95 % confidence interval (p-value < 0.05) as the minimal level of 
significance. All the results were performed in triplicates for all experiments with mean and 
standard deviation. 365 
 
3. RESULTS AND DISCUSSION 
3.1 Hydration (swelling) capacity  
Figure 1 shows the swelling profiles of BLK (Figure 1a) and DL (Figure 1b) MET films in 
PBS and SS with the DL films both showing a linear swelling versus time profiles whilst the 370 
BLK films were less linear. The swelling index in SS pH 6.8 was significantly (p < 0.05) 
lower at each time point compared to PBS at pH 6.8 for all the films (both BLK and DL). 
This may be due to the higher ionic strength of the SS media which plays an important role in 
affecting the swelling of MET films due to its effect on the osmotic gradient with ions and 
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the polymer chains competing for diffusing water molecules. The calculated ionic strengths 375 
for PBS and SS were 0.275M and 0.286M respectively.  Though the difference appears small, 
the SS contained many more types of ions (K+, H+, PO4
3-, Na+ and Cl-), than PBS (K+ and 
PO4
3-) and therefore more likelihood of osmotic competition for the water molecules. The 
effect of ionic strength and pH on the swelling of polymers has been described by Peh and 
Wong, (1999) and the results obtained in the current study for PBS and SS showed 380 
similarities to their reported results. Generally, the BLK films showed higher swelling index 
compared to the DL films in the corresponding respective media (PBS and SS). This suggests 
that the presence of drug slowed down the swelling of the films. 
 
3.2 In vitro mucoadhesion on gelatine gel 385 
The mucoadhesive data for the plasticised BLK and DL films obtained from equilibrating 
gelatine with the two different media (PBS and SS) simulating the buccal mucosa are shown 
in figure 2. The texture analysis results when the gelatine was equilibrated with SS at pH 6.8 
showed lower stickiness (PAF), WOA and cohesiveness compared to when gelatine was 
equilibrated with PBS and the differences were statistically significant (p < 0.05). Once again 390 
this may be due to the difference in ionic strength of the media affecting the hydration of the 
films as observed during the swelling study. In general, the initial stages of mucoadhesion 
involves the hydration of the polymer which is essential to allow the polymer chains to diffuse 
into the chains of the mucosal substrate to allow formation of physical entanglement between 
the chains and establishing of the adhesive forces between the two interacting surfaces 395 
(Bodupalli et al., 2010).  
Hydration and presence of salts have been reported among factors that affect the 
mucoadhesion of polymer based systems for mucosal applications (Salamat-Miller et al., 
2005; Asane et al., 2008; Roy et al., 2009). A slower rate of hydration and swelling of the 
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film, in SS due to presence of extra salts, will therefore slow down the formation of such 400 
physical entanglements between the polymer chains and the chains of the gelatine, with 
resultant decrease in adhesive properties, whilst the reverse was true for gelatine equilibrated 
with PBS. However, since the SS is more representative of the buccal environment, the 
mucoadhesive results using this media is a better indication of the formulation performance 
following buccal administration. Further, the presence of drug slightly increased the 405 
mucoadhesive values (PAF, TWA and cohesiveness), however, this effect did not appear 
significant.  
 
3.3 Drug stability 
Short-term stability studies were performed for DL MET film obtained from ethanolic (20% 410 
v/v) gels containing OME: L-arg 1:2, 0.5% w/w PEG 400, and exposed to two temperature 
conditions 40ºC (± 0.5ºC) and 20ºC ± 0.5ºC) (ICH 2003 guidelines) for a period of three months 
and the results are shown in figure 3. The results of the stability study reveal that there was 
statistically significant (p < 0.05) difference in the drug loss (%) between the films kept in the 
oven (40ºC) and ambient conditions. After 14 days, the percentage of OME remaining at 40ºC 415 
and room temperature were 87% and 80% respectively and whilst the percentage remaining 
after 28 days was 82% and 62% respectively. This might relate to the lower humidity at the 
higher temperature of 40ºC given that OME is highly sensitive to moist conditions due to easy 
hydrolysis. However, the % drug content after 28 days at room temperature remained constant 
at 62% up to 84 days whilst the % content decreased to 47% at 40 ºC, implying that the 420 
accelerated temperature conditions had a greater effect after 4 weeks, and speeded up the 
degradation of the drug in the longer term.  
These findings suggest that overall, films are relatively more stable at room temperature 
conditions over 3 months, though the % loss after 3 months was still quite high in terms of long 
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term storage. Iuna and Bojita (2010) investigated the degradation kinetics of OME at 25ºC and 425 
40.8ºC, confirming the degradation followed zero order kinetics, which was faster at higher 
temperature and relative humidity whilst relatively more stable at 25ºC. The most likely 
implication is that such films in addition to protection from light, will need to be stored in 
airtight blisters or peel packs to avoid contact with atmospheric moisture and must be stored at 
ambient temperatures. This however, requires further investigation to confirm such 430 
proposition. 
 
3.4 In vitro drug dissolution 
3.4.1 Drug release profiles 
The dissolution profile for DL MET films in PBS solution is shown in figure 4. During the 435 
early stage of dissolution, percentage cumulative release versus time plot showed an almost 
linear fit with 55.8 % release within the first 15 minutes and 66.15% after 30 minutes, after 
which the % release was fairly constant. The release data show that the presence of L-arg may 
have the ability to enhance drug solubility; therefore, this facilitates the process of hydration 
as previously reported (Figueiras et al, 2010). This hydration occurs via water penetration 440 
through the process of diffusion and eventual dissolution of the drug within the film matrix. 
After 60 minutes the release was observed to be sustained and might represent complete 
swelling of the hydrated polymer.  
The dissolution profile for DL MET films containing OME were also determined using 
SS to more accurately mimic the environment within the oral cavity in terms of both pH and 445 
ionic strength and shown in figure 4. During the initial stages of dissolution, the % release into 
SS was observed to be lower with 1.08% released in the first 15 minutes after which it gradually 
increased to 18.21% and 21.77% at 45 and 60 minutes respectively, and then the release 
remained largely steady till 120 minutes.  
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The films appeared to show more sustained release in the SS dissolution media. The 450 
release of OME from the MET films could be attributed to the swelling of the polymeric 
network and releasing the drug progressively into the dissolution medium. The results show 
that drug release rates were faster in PBS and the L-arg had little solubilizing effect on the in 
SS due to difference in osmotic pressure and ionic strength as SS contains more salts (sodium, 
chloride and potassium) than PBS. This also confirmed the hydration (swelling data) 455 
suggesting that the ionic strength significantly affects water penetration into the film matrix, 
drug dissolution and subsequent drug release into the dissolution medium. The results further 
suggest that it is important to simulate as closely as possible, the natural environment within 
which a drug is expected to be administered during in vitro experiments to allow more accurate 
in vivo correlations.  460 
Overall, drug release in both media seems to hit a plateau after about 60 minutes 
without achieving 100% release of the drug and this may suggest possible interactions 
between formulation components.  In our previous publication (Khan et al., 2015) we showed 
that the drug which was added originally in crystalline form was present in amorphous form 
or molecularly dispersed within the film matrix. However, the dissolution profiles seem to 465 
correlate with the swelling profiles suggesting that most of the release occurring in the first 
hour occurs via drug diffusion through the swollen gel. For buccal administration, drug 
release is usually measured over only 2 hours to simulate real life application since patients 
cannot hold a dosage form in the cheek for longer than 2 hours without dislodging by tongue 
and teeth movements. 470 
 
3.4.2 Evaluation of drug release mechanisms 
The dissolution data were fitted to different kinetic equations to explain the release kinetics of 
OME from the buccal films. The release parameters obtained from fitting experimental 
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dissolution release data to the different kinetic equation evaluated has been summarised in table 475 
3 (Shoaib et al., 2006). Interpretation of the data was based on the value of the resulting 
regression coefficient. The release kinetics of OME in PBS and in SS both followed 
Korsmeyer-Peppas model as the R2 values were the highest compared to other models. The ‘n’ 
values from the Korsmeyer-Peppas equation, describe the diffusion state or release exponent 
used for elucidation of the drug release mechanism. The ‘n’ value is estimated from linear 480 
regression of log (Mt/M) versus log t plot. Analysis of the experimental data using kinetic 
equations and interpretations of the release exponents (n) gives a better understanding of the 
controlling release mechanism. OME release in PBS showed an ‘n’ value of 0.2 which is less 
than 0.45 indicating that the drug release mechanism followed non-Fickian diffusion. However, 
for SS an ‘n’ value of 2.2 was obtained which is greater than 0.89 therefore follows super case 485 
II transport mechanism of drug release. This indicates controlled drug release with zero-order 
kinetics attributed to the erosion of the polymeric chain matrix.  
 
3.4.3 Comparison of release profiles 
The time to 20% release (t20%) of initial amount of OME present, for each media can be seen 490 
in table 4. The results showed that in SS media, 20% of drug was released in 50 minutes 
whereas in PBS media 20% was released in 5.5 minutes indicating a statistically significant (p 
< 0.05) difference. The t60min in PBS and SS was 70% and 22% respectively which was again 
statistically significant (p = 0.05). These results are attributed to the swelling of the DL films 
within the two media due to difference ionic strength as SS contains more salts (sodium 495 
chloride and sulphate) than PBS as noted previously.  
 
3.5 Ex vivo studies with pig buccal tissue 
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This study investigated the ex vivo permeation of OME released from the DL films and ex vivo 
mucoadhesion properties of these films using a pig buccal tissue which resembles human 500 
buccal mucosa in structure and permeability (Werts, 1991) as well as cell viability of the DL 
films.  
 
3.5.1 Ex vivo buccal permeation studies  
Maintaining buccal tissue integrity and viability during isolation and storage before 505 
experimental testing is crucial to obtaining reliable permeation results (Patel et al., 2012). The 
storage of porcine buccal mucosa in Krebs bicarbonate Ringer solution helped to maintain its 
integrity whiles storage in other solutions such as PBS at 4°C for 24 hours has been reported 
to result in the loss of epithelial integrity (Kulkarni et al., 2010).  
Before a buccal drug delivery system can be optimised, the permeation characteristics 510 
must be investigated to determine the feasibility of this route of administration for the delivery 
of the drug (OME) of interest. The permeability profile of OME released from the DL MET 
films in the presence of L-arg is shown in figure 5. There was a lag period of about 20 minutes 
and then near linearity was observed up to 60 minutes of permeation which followed a first 
order kinetic mechanism. The total cumulative amount of OME permeating over 2 hrs was 515 
275ug/cm2. This suggests that porcine buccal membrane is generally quite permeable to OME 
and also confirms that the OME is released from the MET films. However, there are generally 
other factors which affect the extent of permeability in vivo. One barrier to drug permeability 
in the presence of SS for example, is the enzymatic degradation as it contains moderate level 
of esterases, phosphatases and amylases. Further, due to poor physical contact with the pig 520 
buccal epithelial surface and/or possibly absence or very minimal volume of mucosal fluid 
(mucin) on the membrane, no significant covalent interaction could be established and this 
could affect the extent of permeation. This is possible as the membrane was initially washed in 
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physiological fluid during preparation before mounting on the donor compartment of the Franz-
type diffusion cell.  525 
 
3.5.2 Ex-vivo mucoadhesion evaluation using porcine buccal tissue with texture analyser 
Films are considered one of the most suitable dosage forms for buccal administration in 
children (Nunn and Williams, 2005). Figure 6 illustrates a comparison of the adhesive 
properties of the films on three model mucosal surfaces i.e. gelatine surface equilibrated with 530 
PBS, and gelatine surface with equilibrated with SS and porcine buccal epithelium. SS 
equilibrated gelatine showed the lowest adhesive (PAF, TWA) values compared to PBS 
equilibrated gelatine and porcine epithelium while the lowest cohesiveness was obtained on 
the porcine tissue. Because the mucous was washed with Krebs buffer, the polymer adheres 
directly to the tissue surface rather than to mucous which will have made it travel a shorter 535 
distance before detachment. However, the film on porcine buccal tissue had the highest TWA 
which indicates the possibility of strong hydrogen bond interaction between the entangled 
polymer chains of the hydrated films (due to the presence of hydrogen bond forming groups 
such as OH and COOH) and the buccal mucosa membrane.  
 540 
3.6 MTT assay 
Tissue viability was assessed using 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium 
bromide) (MTT) cytotoxicity study for pure OME, L-arg, BLK film (MET, EtOH 20% v/v), 
BLK film (MET, PEG 400 (0.5% w/w, EtOH 20% v/v), and DL film (MET, PEG 400 (0.5% 
w/w, EtOH 20% v/v, and OME: L-arg 1:2). This is a reduction assay where yellow MTT was 545 
reduced to purple formazan primarily by the action of enzymes which are located inside the 
mitochondria of the viable cells (Koschier et al., 2011). Figure 7 displays the respective cell 
viability data for the samples described above when exposed to Vero cells as measured by MTT 
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assay. The results show a clear profile of the cytotoxity of the pure materials and DL films on 
adherent mammalian cells (Vero cells) with almost 100% cell viability confirming that the pure 550 
drug (OME), starting materials and the drug released from the DL films were non-toxic and 
can be employed for paediatric drug delivery. There are several factors involved in determining 
the successful and safe application of polymers as drugs carriers in humans, with toxicity being 
an important factor. Kendall (2003) revealed that OME is generally regarded as a non-toxic 
drug however, none of the literature have shown a clear profile on the complete absence of 555 
toxicity of OME on endothelial cells. Therefore this study confirms that OME poses no 
physical threats to endothelial cells when used as a drug carrier for potential buccal application 
in paediatric patients. 
 
4. CONCLUSION 560 
The functional properties of OME loaded MET buccal films for paediatric delivery, 
have been characterised. The stability studies suggested that films remained more stable at 
room temperature (ambient ± 0.5ºC) conditions when compared to 40ºC, over a three month 
period though the drug content in both cases was lower than the initial drug loaded and 
therefore require specialised packaging to avoid contact with moisture and should be protected 565 
from light. The swelling, mucoadhesion and in vitro drug release in the presence of PBS was 
higher than when SS was present, attributed to the higher ionic strength of the SS which 
affected the initial rate of polymer hydration. Though most of the literature simulates the buccal 
environment on the basis of the pH alone, our results suggest that this is not sufficient and the 
ionic environment within which drug release and permeation occurs needs to be replicated as 570 
closely as possible. 
The Korsmeyer-Peppas equation best fit the dissolution data in both PBS and SS media. The 
drug release in PBS followed zero order release kinetics via non-Fickian diffusion whilst 
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release in SS followed super case II transport, attributed to both drug diffusion and polymer 
erosion. The films showed enough drug permeability after release of OME which is expected 575 
to ensure therapeutic bioavailability and therefore a potentially useful alternative to oral 
administration via the GI tract. The ex vivo adhesive properties suggest it will provide a long 
enough residence time in the cheek to allow drug permeation, while MTT assay showed that 
all the starting materials and the films were relatively safe for continuous attachment in the 
cheek region, suitable for pediatric patients.  580 
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Figure Legends 
Figure 1 Swelling profiles of plasticised MET DL films cast from ethanolic (20% /v/v) gels 
containing 0.5% w/w PEG 400 and OME: L-Arg 1:2 in two different media [(PBS and SS at 
pH 6.8)] (mean ± SD, (n=3) and MET BLK films cast from ethanolic gels containing 0.5% 585 
w/w PEG 400 in SS at pH 6.8 (mean ± SD, (n=3). 
 
Figure 2 In-vitro mucoadhesion properties (PAF, TWA and cohesiveness) of plasticised BLK 
and DL MET film cast from ethanolic (20% v/v) gels containing OME:L-arg 1:2 using 
mucosal substrate equilibrated with PBS and SS (pH 6.8) (mean ± SD, (n=3)). 590 
 
Figure 3 Plots showing the % OME content for MET DL film during storage at oven 
temperature 40ºC (± 0.5ºC) and room temperature (ambient ± 0.5ºC)  up to three months 
(mean ± SD, (n=3)). 
 595 
Figure  4 Drug dissolution profile of MET DL films prepared from ethanolic (20% v/v) gel 
containing 0.5% w/w PEG 400 and OME: L-Arg 1:2 ratio in PBS at pH 6.8 and SS pH 6.8 
(mean ± SD, (n=3)). 
 
Figure 5 Cumulative permeation curve of OME released from MET film through pig buccal 600 
tissue (mean ± SD, (n=3)). 
 
Figure 6 In-vitro mucoadhesion measurements of MET DL film obtained from ethanolic 
(20% v/v) gels containing 0.5% w/w PEG 400, OME: L-Arg 1:2 ratio and in PBS pH 6.8, SS 
pH 6.8 (gelatine surface) and epithelium of porcine buccal tissue (mean ± SD, (n=3)). 605 
 
Figure 7 MTT assay results, showing cell viability showing pure OME, L-arg, BLK and DL 
films (mean ± SD, (n=3)). (BF = blank film) 
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